Saiertech was founded in September 2005 with a registered capital of Rmb 11 million and launched its building in August 2006. In July 2007, Saiertech kicked off its trial production of 3 batches of national standard Anti Rh(D) Blood Grouping Reagent. The company's capital increased to Rmb 30 million in 2008.

Covering an area of 9,778m2, Saiertech has finished its first phase of construction including its 6,200m2 GMP workshop, 400m2 QA workshop, 400m2 R&D lab, and 1,000m2 Administration area.

With diagnosis-oriented monoclonal antibody (McAb) as its primary product, Saiertech is devoted to developing, producing, and selling diagnosis-oriented McAB Reagents, ELISA kits, TRFIA kits, as well as other bio-medical products.   　

Saiertech has been in long term "production, teaching and research" cooperation with Suzhou University and kept continual and fruitful relationship with a number of well-known research institutes both in China and abroad, including Institut Pasteur, Montpellier Hospital, Nantes University, Kanazawa University, Tokyo University, University of Wuerzburg, and University of Pittsburgh.

Based on the scientific research system of Suzhou University,Saiertech is also in active interaction with other renowned institutions and entities.A mode integrating "capital,technology and market" has taken shape in Saiertech,which also combines producing,teaching and research together to fully put the innovative bio-medical technology into practice and turns into profit. As a bio-tech company expanding into healthcare industry, Saiertech is dedicated to serving for people's health with its advanced bio-medical technology and unique service concept.